Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 30 | 2019 | 132 | 8.960 |
Why?
|
| Hepatitis C, Chronic | 27 | 2019 | 78 | 7.960 |
Why?
|
| Hepacivirus | 27 | 2019 | 73 | 6.270 |
Why?
|
| Interferon-alpha | 19 | 2016 | 66 | 4.060 |
Why?
|
| Ribavirin | 19 | 2016 | 32 | 4.050 |
Why?
|
| Hepatitis C | 12 | 2016 | 65 | 3.700 |
Why?
|
| Polyethylene Glycols | 17 | 2016 | 55 | 3.650 |
Why?
|
| Drug Therapy, Combination | 17 | 2016 | 241 | 1.650 |
Why?
|
| Protease Inhibitors | 4 | 2016 | 15 | 1.480 |
Why?
|
| Proline | 7 | 2019 | 19 | 1.370 |
Why?
|
| Liver Diseases | 3 | 2022 | 41 | 1.360 |
Why?
|
| Sulfonamides | 6 | 2019 | 54 | 1.330 |
Why?
|
| Recombinant Proteins | 19 | 2016 | 251 | 1.280 |
Why?
|
| Gastroenterology | 4 | 2016 | 11 | 1.030 |
Why?
|
| Oligopeptides | 2 | 2016 | 30 | 1.020 |
Why?
|
| Interferons | 3 | 2015 | 13 | 0.990 |
Why?
|
| Liver Transplantation | 4 | 2012 | 79 | 0.990 |
Why?
|
| RNA, Viral | 12 | 2016 | 149 | 0.920 |
Why?
|
| Humans | 50 | 2022 | 29361 | 0.840 |
Why?
|
| Genotype | 11 | 2016 | 405 | 0.820 |
Why?
|
| Societies, Medical | 1 | 2022 | 190 | 0.750 |
Why?
|
| Quinoxalines | 1 | 2019 | 11 | 0.710 |
Why?
|
| Benzimidazoles | 1 | 2019 | 12 | 0.710 |
Why?
|
| Drug Design | 1 | 2019 | 30 | 0.700 |
Why?
|
| Liver | 5 | 2016 | 173 | 0.660 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2016 | 9 | 0.660 |
Why?
|
| Treatment Outcome | 15 | 2016 | 3476 | 0.640 |
Why?
|
| Viral Load | 7 | 2016 | 199 | 0.590 |
Why?
|
| Drug Approval | 2 | 2016 | 30 | 0.580 |
Why?
|
| Drugs, Generic | 1 | 2016 | 4 | 0.570 |
Why?
|
| Thiazoles | 1 | 2016 | 35 | 0.560 |
Why?
|
| Benzothiadiazines | 1 | 2015 | 1 | 0.560 |
Why?
|
| Quinolones | 1 | 2015 | 21 | 0.550 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2012 | 2 | 0.530 |
Why?
|
| Hepatitis B, Chronic | 1 | 2014 | 6 | 0.510 |
Why?
|
| Coinfection | 1 | 2014 | 29 | 0.490 |
Why?
|
| Time Factors | 7 | 2016 | 1618 | 0.490 |
Why?
|
| Editorial Policies | 1 | 2014 | 7 | 0.490 |
Why?
|
| Journal Impact Factor | 1 | 2014 | 15 | 0.480 |
Why?
|
| Middle Aged | 20 | 2016 | 9823 | 0.480 |
Why?
|
| Kidney Transplantation | 2 | 2008 | 125 | 0.480 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 41 | 0.460 |
Why?
|
| Drug Monitoring | 1 | 2013 | 24 | 0.450 |
Why?
|
| United States | 7 | 2022 | 2332 | 0.450 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 2 | 0.430 |
Why?
|
| Male | 23 | 2016 | 15637 | 0.420 |
Why?
|
| Adult | 18 | 2016 | 8604 | 0.420 |
Why?
|
| Interleukins | 1 | 2012 | 37 | 0.420 |
Why?
|
| Graft Rejection | 1 | 2012 | 76 | 0.410 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 78 | 0.410 |
Why?
|
| Female | 22 | 2016 | 16211 | 0.390 |
Why?
|
| Anemia | 2 | 2011 | 97 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 220 | 0.380 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 10 | 0.380 |
Why?
|
| Cyclopropanes | 4 | 2019 | 25 | 0.380 |
Why?
|
| Drug Administration Schedule | 6 | 2016 | 223 | 0.370 |
Why?
|
| Hepatitis B | 1 | 2010 | 19 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 441 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2016 | 340 | 0.330 |
Why?
|
| Transaminases | 1 | 2008 | 6 | 0.330 |
Why?
|
| Heart Transplantation | 1 | 2008 | 38 | 0.320 |
Why?
|
| Aminoisobutyric Acids | 2 | 2019 | 4 | 0.320 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 7 | 0.320 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2008 | 6 | 0.320 |
Why?
|
| Leucine | 2 | 2019 | 15 | 0.320 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2008 | 3 | 0.320 |
Why?
|
| Retreatment | 4 | 2014 | 11 | 0.320 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 145 | 0.300 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 324 | 0.300 |
Why?
|
| HIV Infections | 1 | 2014 | 980 | 0.290 |
Why?
|
| Remission Induction | 3 | 2015 | 96 | 0.280 |
Why?
|
| Treatment Failure | 4 | 2009 | 159 | 0.280 |
Why?
|
| Logistic Models | 3 | 2016 | 407 | 0.270 |
Why?
|
| Liver Cirrhosis | 2 | 2016 | 60 | 0.270 |
Why?
|
| Lactams | 2 | 2015 | 5 | 0.270 |
Why?
|
| Hospital Departments | 1 | 2005 | 9 | 0.270 |
Why?
|
| Ritonavir | 2 | 2014 | 18 | 0.250 |
Why?
|
| Hospital Costs | 1 | 2005 | 68 | 0.250 |
Why?
|
| Nucleotidases | 1 | 2004 | 1 | 0.240 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2004 | 3 | 0.240 |
Why?
|
| Cholestasis | 1 | 2004 | 8 | 0.240 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 16 | 0.240 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 142 | 0.240 |
Why?
|
| Hepatitis C Antibodies | 1 | 2003 | 7 | 0.240 |
Why?
|
| Interferon Type I | 1 | 2003 | 18 | 0.230 |
Why?
|
| Cyclosporine | 1 | 2003 | 15 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 437 | 0.230 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 70 | 0.220 |
Why?
|
| Internship and Residency | 2 | 2016 | 211 | 0.210 |
Why?
|
| Pyrrolidines | 2 | 2019 | 21 | 0.210 |
Why?
|
| History, 20th Century | 1 | 2022 | 84 | 0.210 |
Why?
|
| Follow-Up Studies | 5 | 2014 | 1829 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 161 | 0.190 |
Why?
|
| Molecular Conformation | 1 | 2019 | 15 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 521 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 111 | 0.170 |
Why?
|
| Isoindoles | 2 | 2015 | 2 | 0.170 |
Why?
|
| Carbamates | 2 | 2016 | 12 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2014 | 3273 | 0.150 |
Why?
|
| Double-Blind Method | 4 | 2014 | 503 | 0.150 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 2 | 0.140 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 8 | 0.140 |
Why?
|
| Commerce | 1 | 2016 | 13 | 0.140 |
Why?
|
| Canada | 1 | 2016 | 56 | 0.140 |
Why?
|
| Safety | 1 | 2016 | 45 | 0.140 |
Why?
|
| Quality Control | 1 | 2016 | 43 | 0.140 |
Why?
|
| Quinolines | 1 | 2016 | 16 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 23 | 0.140 |
Why?
|
| Fraud | 1 | 2016 | 21 | 0.140 |
Why?
|
| Retinoids | 1 | 2016 | 5 | 0.140 |
Why?
|
| Carotenoids | 1 | 2016 | 9 | 0.140 |
Why?
|
| Isoquinolines | 1 | 2016 | 14 | 0.140 |
Why?
|
| New Zealand | 1 | 2015 | 13 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 55 | 0.140 |
Why?
|
| Actins | 1 | 2016 | 45 | 0.140 |
Why?
|
| Australia | 1 | 2015 | 44 | 0.140 |
Why?
|
| Deoxycytidine | 1 | 2015 | 31 | 0.140 |
Why?
|
| Biomarkers | 2 | 2016 | 692 | 0.140 |
Why?
|
| Europe | 1 | 2015 | 81 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2016 | 97 | 0.140 |
Why?
|
| Imidazoles | 1 | 2016 | 72 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2016 | 285 | 0.130 |
Why?
|
| Simeprevir | 1 | 2015 | 1 | 0.130 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 2 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2015 | 7 | 0.130 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 15 | 0.130 |
Why?
|
| Phenotype | 1 | 2015 | 357 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 79 | 0.120 |
Why?
|
| Uracil | 1 | 2014 | 5 | 0.120 |
Why?
|
| Macrocyclic Compounds | 1 | 2014 | 5 | 0.120 |
Why?
|
| Anilides | 1 | 2014 | 10 | 0.120 |
Why?
|
| Biopsy | 4 | 2016 | 234 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 144 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2014 | 70 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2012 | 48 | 0.110 |
Why?
|
| Nucleosides | 1 | 2012 | 3 | 0.110 |
Why?
|
| Immunoassay | 1 | 2012 | 43 | 0.110 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 65 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2012 | 64 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 37 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 132 | 0.100 |
Why?
|
| Patient Selection | 1 | 2012 | 232 | 0.090 |
Why?
|
| Hepatitis B virus | 1 | 2010 | 7 | 0.090 |
Why?
|
| Risk Factors | 3 | 2012 | 2446 | 0.090 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 25 | 0.090 |
Why?
|
| Global Health | 1 | 2010 | 55 | 0.090 |
Why?
|
| Prognosis | 1 | 2012 | 840 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2009 | 30 | 0.080 |
Why?
|
| Graft Survival | 1 | 2008 | 98 | 0.080 |
Why?
|
| Aged | 4 | 2014 | 9447 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2008 | 81 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2007 | 64 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 206 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2008 | 81 | 0.070 |
Why?
|
| Mutation | 1 | 2008 | 383 | 0.070 |
Why?
|
| RNA | 1 | 2006 | 39 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2008 | 394 | 0.070 |
Why?
|
| Internal Medicine | 2 | 2016 | 32 | 0.070 |
Why?
|
| Sample Size | 1 | 2005 | 25 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 333 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2012 | 957 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2005 | 19 | 0.070 |
Why?
|
| Valine | 2 | 2016 | 11 | 0.070 |
Why?
|
| Hepatitis | 1 | 2004 | 9 | 0.060 |
Why?
|
| Curriculum | 2 | 2016 | 155 | 0.060 |
Why?
|
| International Cooperation | 2 | 2016 | 32 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2004 | 100 | 0.060 |
Why?
|
| Research Design | 1 | 2005 | 212 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2003 | 26 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2003 | 5 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2003 | 21 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2003 | 24 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2005 | 330 | 0.060 |
Why?
|
| Living Donors | 1 | 2003 | 8 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 28 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 32 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2003 | 55 | 0.060 |
Why?
|
| Probability | 1 | 2003 | 94 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2008 | 1812 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 138 | 0.060 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 21 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 129 | 0.060 |
Why?
|
| General Surgery | 1 | 2003 | 49 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 148 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2002 | 638 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2005 | 1939 | 0.040 |
Why?
|
| Adolescent | 2 | 2014 | 2280 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 1935 | 0.040 |
Why?
|
| Career Choice | 1 | 2016 | 30 | 0.040 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2016 | 1 | 0.040 |
Why?
|
| Isoprostanes | 1 | 2016 | 2 | 0.040 |
Why?
|
| beta Carotene | 1 | 2016 | 7 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2016 | 9 | 0.040 |
Why?
|
| Vitamin A | 1 | 2016 | 7 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 36 | 0.040 |
Why?
|
| Diterpenes | 1 | 2016 | 9 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 8 | 0.040 |
Why?
|
| Hepatic Stellate Cells | 1 | 2016 | 9 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 26 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 130 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 32 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 217 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 124 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 39 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 47 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 391 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 3 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2014 | 8 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 103 | 0.030 |
Why?
|
| 2-Naphthylamine | 1 | 2014 | 4 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 4577 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 495 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 230 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 83 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2012 | 4 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 788 | 0.030 |
Why?
|
| Viremia | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 965 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2012 | 28 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1113 | 0.030 |
Why?
|
| Sex Factors | 1 | 2012 | 496 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 845 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 18 | 0.020 |
Why?
|
| Triglycerides | 1 | 2009 | 41 | 0.020 |
Why?
|
| Cholesterol | 1 | 2009 | 49 | 0.020 |
Why?
|
| Illinois | 1 | 2004 | 241 | 0.010 |
Why?
|
| Public Opinion | 1 | 2003 | 5 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 2003 | 17 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 491 | 0.010 |
Why?
|
| Data Collection | 1 | 2003 | 107 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2003 | 101 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 350 | 0.010 |
Why?
|